Citius Oncology, Inc. Common Stock

Day range

$0.60 – $0.69

Open

$0.63

Prev close

$0.58

Volume

198.61K

Market cap

$61.29M

Shares out

92.98M

P/E

—

P/S

8.63

P/B

1.52

P/FCF

—

ROE

-114.1%

ROA

-41.1%

Debt/Equity

0.16

Div yield

0.00%

As of Oct 23, 2026

• Listing deficiency noticeOct 23, 2026

  On October 19, 2026, Citius Oncology, Inc. received formal notice that Nasdaq granted its request for an extension through April 19, 2027 to evidence compliance with the $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).

• Annual meeting resultsSep 29, 2026

  On September 29, 2026, Citius Oncology, Inc. held its 2026 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, our stockholders elected the following Class II directors for a three-year term expiring at the annual meeting of stockholders to be held in 2029 or until their successors are duly elected and qualified, based on the following votes: Dr. Eugene Holuka, Robert Smith, and Carol Webb.

• Business updateAug 5, 2026

  On August 5, 2026, Citius Oncology, Inc. issued a press release announcing an update on the expanding base of institutional accounts ordering LYMPHIR®.

• Credit facilityMay 6, 2026

  Prior to the warrant inducement transaction, on May 4, 2026, the Company and Citius Pharmaceuticals, Inc., a Nevada corporation (the 'Parent'), entered into a Third Amendment to Promissory Note (the 'Third Amendment'), which amends the promissory note, dated August 16, 2024, as previously amended on September 10, 2025 and December 10, 2025, issued by the Company to the Parent in the original principal amount of $3,800,111 (the 'Promissory Note'), to, among other things, (i) conform the payment and maturity provisions of the Promissory Note to the Subordination Agreement, such that the entire unpaid principal balance of the Promissory Note shall be payable on a date that is 91 days after the Senior Debt has been fully paid and the Loan Agreement has been terminated, (ii) eliminate all prior maturity triggers related to capital raises, issuances of debt or equity securities, or royalty-backed monetizations, (iii) prohibit prepayment of the Promissory Note in cash prior to the new maturity date, and (iv) add a voluntary conversion feature allowing the Parent, subject to the Company's approval, to convert all or a portion of the outstanding principal into shares of common stock at a conversion price equal to $0.90 per share.

• Product or service launchApr 29, 2026

  Citius Oncology, Inc. issued a press release announcing the initial shipment of LYMPHIR™ (denileukin diftitox-cxdl) to Europe through one of its regional distribution partners.

Days to cover

2.2

Short interest

289.72K

Avg volume

129.39K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
  positiveBenzinga· Feb 13, 2026
• Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
  positiveBenzinga· Feb 13, 2026
• Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
  positiveBenzinga· Dec 10, 2025
• Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
  positiveBenzinga· Dec 9, 2025
• Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
  neutralBenzinga· Sep 10, 2025